Patents Issued in August 22, 2024
  • METHODS AND COMPOSITIONS FOR TREATING CANCER
    Publication number: 20240277699
    Abstract: This disclosure relates to methods and compositions for treating cancer by administering opioid growth factor receptor (OGFR) antagonists. In particular, the present disclosure relates to methods of administering OGFR antagonists locally to the site of cancer cells in the patient diagnosed with cancer.
    Type: Application
    Filed: April 26, 2024
    Publication date: August 22, 2024
    Applicant: Zetagen Therapeutics, Inc.
    Inventors: Bryan S. Margulies, Nikhil A. Thakur
  • COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INTERSTITIAL CYSTITIS
    Publication number: 20240277700
    Abstract: Pharmaceutical compositions and methods of treating or preventing interstitial cystitis of the bladder or the symptoms thereof in a patient that includes administering an H1 receptor antagonist and an H2 receptor antagonist to the patient.
    Type: Application
    Filed: September 21, 2022
    Publication date: August 22, 2024
    Inventors: Reed B. Hogan, II, Thomas P. Dooley, Douglas R. Paul
  • PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY
    Publication number: 20240277701
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Application
    Filed: September 15, 2023
    Publication date: August 22, 2024
    Inventors: Shin-San Michael Su, Lenny Dang
  • INJECTABLE FORMULATION
    Publication number: 20240277702
    Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.
    Type: Application
    Filed: December 15, 2023
    Publication date: August 22, 2024
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU
  • TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF
    Publication number: 20240277703
    Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
    Type: Application
    Filed: December 18, 2023
    Publication date: August 22, 2024
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiharu INOUE
  • VASOCONSTRICTION COMPOSITIONS AND METHODS OF USE
    Publication number: 20240277704
    Abstract: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH from about 4.0 to about 7.5.
    Type: Application
    Filed: April 23, 2024
    Publication date: August 22, 2024
    Inventor: Gerald Horn
  • DOSAGE REGIMENS FOR ECUBECTEDIN
    Publication number: 20240277705
    Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, for use in the treatment of cancers. The present invention also relates to a compound of formula I or a pharmaceutically acceptable salt or ester thereof, for use in the treatment of cancer at certain dosage regimens.
    Type: Application
    Filed: May 19, 2022
    Publication date: August 22, 2024
    Inventors: Carmen Kahatt, Pilar Lardelli, Cristian Fernandez, Arturo Soto
  • METHODS AND COMPOSTITIONS FOR TARGETING PD-L1
    Publication number: 20240277706
    Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Application
    Filed: January 17, 2024
    Publication date: August 22, 2024
    Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez
  • Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus
    Publication number: 20240277707
    Abstract: The present invention concerns an Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Application
    Filed: March 26, 2024
    Publication date: August 22, 2024
    Applicant: BERGENBIO ASA
    Inventors: James Bradley LORENS, Gro GAUSDAL
  • Use of [1,2,4] Triazolo [4,3-B] Pyridazine Derivative For Preventing and Treating Senescence and Senescence-Related Diseases
    Publication number: 20240277708
    Abstract: The present disclosure relates to the field of medical technology, particularly relates to use of [1,2,4]triazolo [4,3-B]pyridazine derivatives for preventing and treating senescence and senescence-related diseases. In particular, the present disclosure finds that C1632 has significant anti-senescence, anti-fibrosis and anti-vascular calcification effects. C1632 is a known small molecule drug which can be dissolved in water, ethanol or DMSO, it has good thermal stability, low cytotoxicity, good safety profile, good pharmacokinetic properties, and can be flexibly administered in a variety of ways comprising oral administration, intraperitoneal injection, intramuscular injection and intravenous injection. C1632 can be used as a safe, effective and convenient candidate drug.
    Type: Application
    Filed: November 29, 2023
    Publication date: August 22, 2024
    Applicant: The Eighth Affiliated Hospital, Sun Yat-Sen University
    Inventors: Chen XIE, Yanlian CHEN, Hui HUANG, Tingting ZHANG
  • Compositions And Methods For The Treatment Of Alopecia
    Publication number: 20240277709
    Abstract: Embodiments relate to compositions and methods for the treatment of hair loss, which can include treatment of alopecia, via an application of a composition including an alkalizing agent and/or a sulfotransferase enzyme. The composition can be formulated to be an orally administered composition. In some embodiments, the composition is used to increase the response of minoxidil.
    Type: Application
    Filed: April 4, 2023
    Publication date: August 22, 2024
    Inventor: Ofer A. Goren
  • PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER AND USE THEREOF
    Publication number: 20240277710
    Abstract: A pharmaceutical composition for the treatment of cancer and a use thereof are provided. The pharmaceutical composition consists of an FAK inhibitor and a CD44 inhibitor. Also provided is a drug combination of an FAK inhibitor and a CD44 inhibitor for the treatment of cancer. The CD44 inhibitor and FAK inhibitor drug combination can have synergistic effects, significantly improving tumor inhibition effects, reducing toxic side effects, and overcoming tumor drug resistance.
    Type: Application
    Filed: May 24, 2022
    Publication date: August 22, 2024
    Inventors: Jing LI, Wu DU, Yongxu HUO, Xinghai LI
  • COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA
    Publication number: 20240277711
    Abstract: cMET inhibitors can be used in the treatment of glioblastoma, including disseminated glioblastoma harboring MET amplification.
    Type: Application
    Filed: June 2, 2022
    Publication date: August 22, 2024
    Applicant: Merck Patent GmbH
    Inventors: Claudia-Nanette GANN, Ilhan Celik, Nazanin Majd, John Frederick de Groot, Michael Weller
  • TREATMENT AND PREVENTION OF DEVELOPMENTAL DISORDERS AND MENTAL DISEASES
    Publication number: 20240277712
    Abstract: The present invention aims at therapeutics to treat and/or prevent Rett syndrome (RTT), autism spectrum disorders or schizophrenia for which no curative therapy has yet been found. The invention relates to pharmaceutical compositions for preventing or treating Rett syndrome (RTT), autism spectrum disorders, or schizophrenia, which comprises a reverse transcription inhibitor for retrotransposon L1.
    Type: Application
    Filed: June 13, 2020
    Publication date: August 22, 2024
    Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kinichi NAKASHIMA, Hideyuki NAKASHIMA, Alysson Renato MUOTRI
  • Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations
    Publication number: 20240277713
    Abstract: The present disclosure provides methods of administering belumosudil mesylate salt to certain subpopulations of patients with cGVHD.
    Type: Application
    Filed: March 27, 2024
    Publication date: August 22, 2024
    Applicant: Kadmon Corporation, LLC
    Inventor: Jeegar P. Patel
  • USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS
    Publication number: 20240277714
    Abstract: The present disclosure relates to combinations of inhibitors of SOS1 and inhibitors of RAS useful in the treatment of diseases or disorders.
    Type: Application
    Filed: April 8, 2022
    Publication date: August 22, 2024
    Inventors: Grace J. Lee, David Church Montgomery, Elsa Quintana, Christopher J. Schulze, Jacqueline Smith, David E. Wildes
  • COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT
    Publication number: 20240277715
    Abstract: The present invention relates to novel combination therapies for the treatment of proliferative disorders, such as, for example, cancer. The combination therapies comprises the administration of a METTL3 inhibitor in combination with (i) an immune oncology agent or therapy; (ii) a BCL2 inhibitor, or a pharmaceutically acceptable salt thereof; (iii) an anthracycline topoisomerase 2 inhibitor, or a pharmaceutically acceptable salt thereof; (iv) cytarabine, or a pharmaceutically acceptable salt thereof; (v) a hypomethylating agent, or a pharmaceutically acceptable salt thereof; or (vi) a FLT3 inhibitor, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 1, 2022
    Publication date: August 22, 2024
    Inventors: Oliver Lars Rausch, Mark Robert Albertella, Yaara Ofir-Rosenfeld, Lina Vasiliauskaite
  • Suppressive T Cell Populations and Methods of Cancer Immunotherapy
    Publication number: 20240277716
    Abstract: The present invention includes methods of treating cancer in a patient, the method comprising the steps of: (a) providing or obtaining a sample from a patient; (b) determining at least one of a level or activity of at least one of: T follicular regulatory (TFR), ST2 Treg, highly suppressive Treg, activated Treg, or effector Treg cells in the sample; (c) comparing the at least one level or activity of the T cells in the sample to a level or activity of the T cells in a reference sample, respectively, for a specific tumor type or a healthy subject; and (d) if the patient has the at least one of the high level or activity of the T cells systemically as compared to the reference sample, then administering a cancer therapy to the patient that comprises a modified dosage or administration of a Phosphoinositide 3-kinase (PI3K) inhibitor.
    Type: Application
    Filed: June 3, 2022
    Publication date: August 22, 2024
    Inventors: Pandurangan Vijayanand, Christian Ottensmeier, Simon Eschweiler, Mitchell Kronenberg
  • APPLICATION OF GANCICLOVIR IN PREPAPRATION OF MEDICINE FOR TREATING ALLERGIC RHINITIS
    Publication number: 20240277717
    Abstract: Ganciclovir (GCV) is a heterocyclic compound containing a purine ring. An application of the GCV in preparation of a medicine for treating allergic rhinitis is provided, in which the GCV is used as an only active component or use the GCV in combination with another medicine. Studies have shown that the GCV can effectively ameliorate symptoms of AR (allergic rhinitis) patients who are ineffective to anti-allergic medicine treatment in clinical and improve their quality of life. It is found from transcriptomics that the GCV regulates the function of nasal mucosal cilium cells, goblet cells and leukocytes. It is also found that the GCV may change immune balance of body by increasing regulatory T cells, thereby alleviating allergic symptoms in vitro peripheral blood mononuclear cells (PBMCs) medicine test.
    Type: Application
    Filed: July 26, 2023
    Publication date: August 22, 2024
    Inventor: Jianjun Chen
  • USE OF ISTRADEFILLIN TO REDUCE ORGAN FIBROSIS
    Publication number: 20240277718
    Abstract: The present invention concerns istradefylline use for the reduction of organ fibrosis.
    Type: Application
    Filed: May 30, 2022
    Publication date: August 22, 2024
    Inventors: Alessandra Bitto, Francesco Squadrito, Domenica Altavilla, Natasha Irrera
  • NOREPINEPHRINE REUPTAKE INHIBITORS FOR TREATING SLEEP APNEA
    Publication number: 20240277719
    Abstract: Methods of treating sleep apnea and snoring comprising administering a norepinephrine reuptake inhibitor, optionally in the absence of an antimuscarinic agent, and optionally as a monotherapy, are described herein. Pharmaceutical compositions comprising norepinephrine reuptake inhibitors, such as edivoxetine and viloxazine, are also described.
    Type: Application
    Filed: June 17, 2022
    Publication date: August 22, 2024
    Inventors: Luigi TARANTO-MONTEMURRO, Ronald FARKAS, David P. WHITE, Lawrence G. MILLER
  • STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF
    Publication number: 20240277720
    Abstract: The disclosure provides pharmaceutical compositions comprising a stabilized pharmaceutically acceptable salt of apilimod, and one or more pharmaceutically acceptable excipients, and related compositions and methods for their use in treating neurodegenerative diseases or disorders, cancer, and viral infections.
    Type: Application
    Filed: January 11, 2024
    Publication date: August 22, 2024
    Inventors: Keith Fandrick, Paul Beckett, Lawrence S. Melvin, JR., Peter Ronald Young, Joan Edwards
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20240277721
    Abstract: The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. In some embodiments, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat lung cancer, e.g., non-small cell lung cancer.
    Type: Application
    Filed: February 2, 2024
    Publication date: August 22, 2024
    Inventors: Maria Alejandra RAIMONDI, Dorothy BRACH
  • CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT
    Publication number: 20240277722
    Abstract: The present invention provides a combination of a substituted heterocyclyl derivative of formula (I) or a pharmaceutically acceptable salt thereof which is a CDK7 inhibitor along with an anti-cancer agent or a prodrug thereof, and a method of treating and/or preventing cancer in a subject, comprising administering to the subject a compound of formula (I) conjointly with the anti-cancer agent.
    Type: Application
    Filed: May 27, 2022
    Publication date: August 22, 2024
    Inventors: LEENA KHARE, Akhil KUMAR, Ramulu PODDUTOORI
  • ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20240277723
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 15, 2024
    Publication date: August 22, 2024
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J.N. WIGLE, Masashi SEKI, Suji SHIROTORI, Satoshi KAWANO
  • COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
    Publication number: 20240277724
    Abstract: The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a BET protein inhibitor, 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-1,4-benzoxazin-3(4H)-one, wherein the combination is unexpectedly synergistic.
    Type: Application
    Filed: October 26, 2023
    Publication date: August 22, 2024
    Inventors: Matthew Stubbs, Phillip C. Liu
  • PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR
    Publication number: 20240277725
    Abstract: Pharmaceutical compositions comprising filgotinib maleate Form I and uses thereof are described herein.
    Type: Application
    Filed: April 5, 2024
    Publication date: August 22, 2024
    Inventors: David Alonzo, Bei Li, Dimitrios Stefanidis
  • PHARMACEUTICAL COMPOSITION COMPRISING MELOXICAM
    Publication number: 20240277726
    Abstract: The present invention relates to novel pharmaceutical composition comprising meloxicam for the treatment of acute pain, wherein the composition comprises at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof.
    Type: Application
    Filed: November 3, 2021
    Publication date: August 22, 2024
    Inventors: Pankaj Devidas Patil, Vivekanand Khyamgonde, Ritesh Kakaria, Ashish Jaiswal, Akhilesh Dixit, Santanu Chakraborty, Amit Antarkar, Abhijit Deshmukh, Jeffrey P. Smith
  • CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE
    Publication number: 20240277727
    Abstract: The invention provides compounds of Formula (1), or pharmaceutically acceptable salts The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
    Type: Application
    Filed: September 5, 2023
    Publication date: August 22, 2024
    Inventors: Bridget McCarthy Cole, James Lamond Ellis
  • FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER
    Publication number: 20240277728
    Abstract: Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.
    Type: Application
    Filed: April 26, 2024
    Publication date: August 22, 2024
    Applicant: Glytech LLC
    Inventor: Daniel C. Javitt
  • METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT
    Publication number: 20240277729
    Abstract: The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an SGLT2 inhibitor.
    Type: Application
    Filed: March 6, 2024
    Publication date: August 22, 2024
    Inventors: Marion WIENRICH, Eric Williams MAYOUX
  • SUPPRESSION OF COVID-19 REPLICATION BY COVID-19 ENTRY INHIBITORS
    Publication number: 20240277730
    Abstract: The present invention relates to compounds, compositions, and methods, for treating viral infections. In particular, entry inhibitor compounds are disclosed for treatment of coronavirus infections, including SARS-COV-1 and SARS-COV-2 infections. The compounds bind to the interface of a SARS-COV-2 spike protein receptor binding domain (RBD) and a host cell ACE-2 receptor. The entry inhibitor compounds show antiviral activity, favorable kinetics, and temporally act at the entry of SARS-COV-2 infection. In embodiments, the compounds are used as medicaments for the inhibition of viral replication including SARS-COV-1 and/or SARS-COV-2 replication, for the treatment or prophylaxis of viral infections including SARS-COV-1 and SARS-COV-2 infections, and/or for the treatment or prophylaxis of an illness due to SARS-COV-1 and SARS-COV-2 infections.
    Type: Application
    Filed: March 3, 2022
    Publication date: August 22, 2024
    Inventors: Kamlendra Singh, Siddappa Byrareddy, Arpan Acharya
  • 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS
    Publication number: 20240277731
    Abstract: The present invention relates to certain cortexolone derivatives of formula (I) and the use of the same as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of the pharmaceutical compositions as antitumor medicinal products.
    Type: Application
    Filed: March 1, 2024
    Publication date: August 22, 2024
    Applicant: COSMO TECHNOLOGIES LTD.
    Inventor: Mara GERLONI
  • COMPOSITIONS AND METHODS FOR TREATING BRAIN-GUT DISORDERS
    Publication number: 20240277732
    Abstract: The present application relates generally to compositions and methods for treating and/or preventing a variety of symptoms and brain-gut disorders related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.
    Type: Application
    Filed: December 5, 2023
    Publication date: August 22, 2024
    Applicant: Enterin, Inc.
    Inventors: Michael Zasloff, Denise Barbut
  • OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20240277733
    Abstract: Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R6, R7, R8, and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: March 13, 2024
    Publication date: August 22, 2024
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella
  • COMPOSITION COMPRISING LIPOIC ACID AND VITAMIN D FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES AND PERIPHERAL NEUROPATHIES
    Publication number: 20240277734
    Abstract: The present invention regards a composition comprising lipoic acid, or an acceptable pharmaceutical or food grade salt thereof or a derivative thereof, and a vitamin D, preferably vitamin D3 and/or vitamin D2. Furthermore, the present invention regards said composition for use in a method for the treatment of neurodegenerative diseases and/or for the treatment of peripheral neuropathies.
    Type: Application
    Filed: April 25, 2024
    Publication date: August 22, 2024
    Inventor: Lorenzo SECONDINI
  • Methods Of Treating Parkinson’s Disease and/or Lewy Body Disease or Disorder(s)
    Publication number: 20240277735
    Abstract: The present disclosure relates to a method of treating Parkinson's Disease and/or Lewy body disease or disorder(s), including Parkinson's disease dementia and dementia with Lewy bodies, comprising administering to a subject ATH-1017.
    Type: Application
    Filed: April 24, 2024
    Publication date: August 22, 2024
    Applicant: Athira Pharma, Inc.
    Inventors: Hans J. Moebius, Xue Hua, Kevin Church, William Walker, Leen H. Kawas
  • USE OF PSILOCYBIN IN THE TREATMENT OF NEUROLOGICAL BRAIN INJURY AND MIGRAINES
    Publication number: 20240277736
    Abstract: Methods for the treatment of a brain injury or a migraine in a mammal including administering a therapeutically effective amount of psilocybin or a pharmaceutically acceptable salt or solvate thereof, to a mammal in need thereof. Use of a pharmaceutical composition including psilocybin or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients for the treatment of a brain injury or a migraine in a mammal.
    Type: Application
    Filed: March 18, 2021
    Publication date: August 22, 2024
    Applicant: Revive Therapeutics Ltd
    Inventor: Fabio Andrea Chianelli
  • METHOD FOR GENERATING DRY POWDER SUITABLE FOR INHALATION ADMINISTRATION OF ANTIMICROBIAL PHOSPHOLIPID COMPOSITIONS
    Publication number: 20240277737
    Abstract: A method for treating an infection in a subject is provided. The method includes administering to the subject, via an oral inhalation route, an amount of a composition that is effective to inhibit the infection. The composition contains a phosphatidylglycerol such as POPG.
    Type: Application
    Filed: August 26, 2022
    Publication date: August 22, 2024
    Inventors: Ajay Gupta, Luca Serratore, Jack Sorrell, Jasmine Ahad
  • GAMETOCYTOCIDAL COMPOUND
    Publication number: 20240277738
    Abstract: The present invention relates to a compound for the inhibition of the transmission of malaria in humans, a pharmaceutical composition comprising said compound, and a method for the inhibition of the transmission of malaria in humans comprising the administration of said compound.
    Type: Application
    Filed: April 29, 2024
    Publication date: August 22, 2024
    Inventors: Jana Held, Lais Pessanha de Carvalho, Sara Grõger Otero, Peter G. Kremsner
  • NUTRITONAL COMPOSITIONS FOR GUT BARRIER FUNCTION
    Publication number: 20240277739
    Abstract: The present invention concerns nutritional compositions for infants and young children that are high in oleic acid and low in palmitic acid and comprise galacto-oligosaccharides, in particular including beta1,3?-galactosyllactose. The nutritional compositions are particularly advantageous for improving intestinal barrier function.
    Type: Application
    Filed: July 1, 2022
    Publication date: August 22, 2024
    Applicant: N.V. Nutricia
    Inventors: Selma Paulien Wiertsema, Saskia Adriana Overbeek, Ingrid Brunhilde Renes, Lauriane Emmanuelle Melanie Schwebel
  • TREATMENT OF KNOWN AND UNKNOWN VIRAL INFECTION WITH LIPID AGENTS
    Publication number: 20240277740
    Abstract: The present invention provides compositions, systems, kits, and methods for treating a subject with a known or unknown enveloped or non-enveloped viral infection (e.g., an unknown virus, RSV, ADV, SARS-CoV2, CHKV, DENV, HSV-1, HSV-2, EBOV, MARV, ZIKV, or a weaponized virus) by administering or providing a composition comprising a lipid agent selected from: a sulfatide, a sulfatide analog, a ceramide, a lipid moiety comprising a ceramide, a sulfoglycolipid, a sulfogalactolipid, a glycosphingolipid, a seminolipid, or a sphingomyelin. In some embodiments, the compositions reduce lung or systemic inflammation in the subject and/or inhibit viral infection. In certain embodiments, the compositions herein are employed to stop a natural pandemic or a biological attack (e.g., with new or weaponized viruses).
    Type: Application
    Filed: May 12, 2021
    Publication date: August 22, 2024
    Inventor: Jason R. Bond
  • AGENT FOR PREVENTING OR AMELIORATING ALZHEIMER'S DISEASE
    Publication number: 20240277741
    Abstract: The purpose of the present invention is to provide an agent for preventing or ameliorating Alzheimer's disease, said agent being able to effectively suppress the accumulation of amyloid ? proteins using a safe material, which has been used in foods for many years, and improve spontaneous alternation behavior change ratio. Ceramides (in particular, a glucosylceramide originating in Amorphophallus konjac) can effectively suppress the accumulation of amyloid ? proteins and thus enables the prevention or amelioration of Alzheimer's disease.
    Type: Application
    Filed: April 29, 2024
    Publication date: August 22, 2024
    Applicant: DAICEL CORPORATION
    Inventors: Kaori TAKAHASHI, Katsuyuki MUKAI, Yasuyuki IGARASHI, Kohei YUYAMA
  • TRANSLATION INHIBITOR WITHOUT OCCUPYING RIBOSOME RESOURCES AS ANTI-TUMOR DRUG
    Publication number: 20240277742
    Abstract: Provided is a translation inhibitor without occupying ribosome resources. The translation inhibitor without occupying ribosome resources shows a good anti-tumor effect and is highly safe, and can be used in preparation of an anti-tumor drug.
    Type: Application
    Filed: February 15, 2024
    Publication date: August 22, 2024
    Inventors: Gong ZHANG, Yang CHEN, Zhuo YU
  • RESTORING PHYSIOLOGY WITH SMALL MOLECULE MIMICS OF MISSING PROTEINS
    Publication number: 20240277743
    Abstract: Disclosed are methods for treating a disease or condition characterized by decreased expression or reduced function of an ion channel, comprising administering to a subject in need thereof a therapeutically effective amount of a pore-forming polyene macrolide or pore-forming derivative thereof. For example, the pore-forming polyene macrolide may be amphotericin B (AmB), nystatin, or natamycin. The methods can be used to treat cystic fibrosis.
    Type: Application
    Filed: January 5, 2024
    Publication date: August 22, 2024
    Inventors: Martin D. Burke, Alexander G. Cioffi, Katrina A. Muraglia, Jennifer Hou, Anthony S. Grillo
  • TREATMENT OF CHEMORESISTANT CANCER CELLS
    Publication number: 20240277744
    Abstract: Use of Cymarin or a structural analog thereof to treat cancer or a combination of cancers, any one of which or all of which are a chemoresistant cancer or chemoresistant cancers or the like. In various examples, a cancer is pancreatic cancer, colon cancer, lung cancer, breast cancer, prostate cancer, or the like, any of which may be a chemoresistant cancer, or any combination thereof. In various examples, Cymarin or a structural analog thereof potentiates a chemotherapeutic agent for the treatment of a chemoresistant cance. In various examples, a composition, which may be a pharmaceutical composition, comprises Cymarin or a structural analog thereof a combination thereof.
    Type: Application
    Filed: February 12, 2024
    Publication date: August 22, 2024
    Inventors: Shuibing Chen, Todd R. Evans
  • PEMAFIBRATE AND/OR TOFOGLIFLOZIN FOR USE IN TREATING LIVER DISEASE
    Publication number: 20240277745
    Abstract: Pemafibrate, tofogliflozin, or combinations thereof for use in treating human patients with liver diseases, particularly NASH patients suffering from liver stiffness or liver fibrosis, NASH patients with lobular inflammation, NASH patients with elevated LDL-C, and NASH patients with healthy triglyceride levels.
    Type: Application
    Filed: May 25, 2022
    Publication date: August 22, 2024
    Applicant: KOWA COMPANY, LTD
    Inventors: Noboru KANETA, Ryu OSHIMA, Shona Sanchita PENDSE, Ryohei TANIGAWA
  • OPHTHALMIC NANO-DISPERSION COMPOSITION, A METHOD OF PREPARATION THEREOF, AND FORMULATION FOR CORNEAL EPITHELIAL WOUND HEALING
    Publication number: 20240277746
    Abstract: Provided is a pharmaceutical solid-in-oil nano-dispersion composition that may include ascorbic acid or a astable derivative thereof, a surfactant coating the ascorbic acid or its derivative and an oil vehicle, wherein the ascorbic acid or its derivative are uniformly dispersed in the solid-in-oil nano-dispersion composition. In addition to that, the present disclosure provides a method of preparing the solid-in-oil nano-dispersion composition and formulations thereof. Also, after administration the S/O nano-dispersion based dosage form to subject, it will improve the corneal epithelial wounds healing.
    Type: Application
    Filed: June 17, 2021
    Publication date: August 22, 2024
    Applicant: THE UNIVERSITY OF JORDAN
    Inventors: Hatim ALKHATIB, Mai JABER, Bahaa Al Din JABER
  • Compounds for Treating Genetic Diseases
    Publication number: 20240277747
    Abstract: Provided are 13-membered ribosome targeting compounds that can be used to treat genetic diseases, including genetic diseases that are associated with a premature termination codon mutation or other nonsense mutation. The compounds can induce and/or promote readthrough of the premature termination codon mutation. Also provided are pharmaceutical compositions containing the compounds, methods of using the compounds and processes for making the compounds.
    Type: Application
    Filed: May 31, 2022
    Publication date: August 22, 2024
    Inventors: Roger B. Clark, Yoshitaka Ichikawa, Wesley Francis Austin, Shuhao Shi, Wenying Wang, Xiben Li, Ivan T. Jewett
  • VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
    Publication number: 20240277748
    Abstract: The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir.
    Type: Application
    Filed: October 11, 2023
    Publication date: August 22, 2024
    Inventors: Jeffrey Scott DePue, Suresh Kumar Tipparaju, Helge Alfred Reisch, Datong Tang, Kishore Ramachandran